Introduction
The pharmaceutical and healthcare sector is one of the most sensitive areas of Turkish Competition Law. Medicines, medical devices, hospitals, private healthcare institutions, laboratories, pharmacies, health insurance companies, digital health platforms and medical technology businesses operate in markets where competition directly affects prices, access, quality, innovation and patient welfare.
Unlike ordinary commercial markets, the healthcare sector is heavily regulated. Medicines may be subject to licensing, reimbursement rules, price controls, prescription requirements, pharmacovigilance obligations, public procurement rules and distribution controls. Medical devices and health technologies may also be regulated by sector-specific rules. Private hospitals and healthcare service providers operate within a complex structure involving patients, insurers, doctors, public institutions, suppliers and technology providers. This complexity makes competition law compliance more important, not less important.
The central legislation is Law No. 4054 on the Protection of Competition. Its purpose is to prevent agreements, decisions and practices that restrict competition in goods and services markets, prevent abuse of dominance and protect competition through regulatory and supervisory measures. The law applies to agreements and conduct affecting markets in Turkey, including abuse of dominance and mergers or acquisitions that may significantly decrease competition.
For pharmaceutical and healthcare companies, Turkish Competition Law may apply to pricing discussions, supply arrangements, distribution agreements, exclusive dealership models, hospital procurement, pharmacy practices, tender participation, health insurance networks, labor market arrangements, data sharing, digital platforms, mergers and acquisitions, licensing deals, R&D cooperation and patient access strategies.
1. Why Competition Law Matters in the Healthcare Sector
Competition law in healthcare is not only about protecting companies from unfair market behavior. It is also about protecting patients, public budgets, innovation and access to essential products. If pharmaceutical companies coordinate prices, public institutions may pay more for medicines. If medical device suppliers rig tenders, hospitals may face inflated procurement costs. If dominant suppliers refuse to provide essential inputs, patients may lose access to important treatments. If private hospitals coordinate commercial terms with insurers, patients may face reduced choice or higher costs.
The Turkish Competition Authority’s own activity shows that healthcare is not a peripheral enforcement area. The Authority’s 2023 annual report noted that food, machinery and healthcare services were among the sectors with the highest number of competition infringement-related activity in that year. In 2026, the Authority announced a formal investigation concerning undertakings active in health insurance, private healthcare institutions and technical or operational support services, showing that the interface between insurance and healthcare services remains a current enforcement priority.
This means that companies in the pharmaceutical and healthcare sector should not assume that regulatory supervision by health authorities replaces competition law. A company may comply with health regulations but still violate competition law if it engages in anti-competitive agreements, abuse of dominance, bid rigging, resale price maintenance or unlawful information exchange.
2. Article 4: Anti-Competitive Agreements in Pharmaceuticals and Healthcare
Article 4 of Law No. 4054 prohibits agreements, concerted practices and decisions of associations of undertakings that have as their object, effect or likely effect the prevention, distortion or restriction of competition in a market for goods or services. The provision expressly covers price fixing, market allocation, controlling supply or demand, restricting competitors’ activities, discrimination and tying practices.
In the pharmaceutical and healthcare sector, Article 4 risks may arise in many ways. Competing pharmaceutical companies may exchange future price or launch information. Medical device suppliers may coordinate tender bids. Private hospitals may coordinate prices, package terms or insurer negotiations. Laboratories may agree not to compete for certain hospital contracts. Wholesalers may exchange stock and supply information in a way that reduces uncertainty. Trade associations may publish recommended fees or organize sensitive data exchanges.
Article 4 is not limited to written agreements. Informal understandings, WhatsApp messages, meeting notes, association discussions, parallel conduct supported by evidence and indirect coordination may all be relevant. In a sector where companies frequently interact through congresses, professional associations, public consultations, tenders and supply chains, this risk is practical and constant.
3. Cartel Risks in Pharmaceutical and Healthcare Markets
Cartels are among the most serious competition law violations. In healthcare markets, cartel conduct may be particularly harmful because it can affect public procurement budgets and patient access. Price fixing, market sharing, customer allocation, output restriction and bid rigging may all fall within the scope of Article 4.
For example, pharmaceutical suppliers should not coordinate future price increases, reimbursement strategies, discount levels or supply quantities. Medical device suppliers should not agree who will win hospital tenders. Diagnostic laboratories should not divide private hospital customers. Competing private hospitals should not agree on minimum patient service prices or common commercial terms with insurers.
The risk is not limited to direct competitors sitting in the same room and signing a cartel agreement. Competitors may coordinate through trade associations, consultants, distributors, common suppliers, health platforms or digital pricing tools. The Turkish Competition Law framework also recognizes concerted practices; where an agreement cannot be proven, similarities in price changes, supply-demand balance or operational regions may create a presumption of concerted practice, although parties may rebut it with economic and rational explanations.
4. Public Tenders and Bid Rigging in Healthcare Procurement
Public tenders are a major risk area in healthcare. Medicines, vaccines, medical devices, diagnostic equipment, laboratory services, hospital supplies, imaging systems, consumables and healthcare IT systems may be purchased through public or institutional procurement processes.
Bid rigging may occur when bidders coordinate their conduct instead of competing independently. This may include cover bidding, bid suppression, bid rotation, market allocation or coordinated subcontracting. A supplier may agree to submit a deliberately high bid so another supplier wins. Competitors may take turns winning tenders. Companies may divide hospitals, regions or product categories among themselves.
Healthcare procurement is particularly sensitive because tenders often involve essential products, public resources and continuity of patient care. Companies participating in Turkish healthcare tenders should implement strict tender compliance procedures. Employees should not discuss bid prices, participation plans, technical offers, customer allocation, discounts or tender strategy with competitors.
Joint bidding or consortium structures may be legitimate where companies cannot individually satisfy technical or capacity requirements. However, such cooperation should be objectively necessary, documented and legally reviewed. A joint bid between companies that could independently compete may raise competition concerns if its real effect is to reduce rivalry.
5. Distribution Agreements and Wholesaler Relations
Pharmaceutical and healthcare products often move through complex distribution channels. A manufacturer may supply wholesalers, authorized distributors, hospitals, pharmacies, clinics, laboratories or public institutions. Medical device companies may appoint regional distributors, exclusive dealers or service providers. These vertical relationships may create efficiencies, but they must be structured carefully.
The Turkish Competition Authority’s Guidelines on Vertical Agreements define vertical agreements as agreements between undertakings operating at different levels of the production or distribution chain for the purchase, sale or resale of goods or services. The Guidelines also explain that vertical agreements can improve production and distribution and may increase inter-brand competition, but their exemption depends on legal conditions.
For healthcare companies, typical vertical risks include resale price maintenance, exclusive distribution, customer restrictions, passive sales restrictions, online sales restrictions, non-compete obligations, exclusive supply, selective distribution and tying. These risks are especially important where the supplier has market power, the product is specialty or life-critical, or the distributor controls access to key hospitals or regions.
6. Resale Price Maintenance in Pharmaceutical and Medical Device Distribution
Resale price maintenance occurs when a supplier restricts the buyer’s freedom to determine its resale price. Under the Vertical Guidelines, fixed or minimum resale prices for the buyer are absolutely prohibited. The Guidelines also explain that indirect methods, such as penalties for failing to comply with recommended prices, may amount to indirect resale price maintenance.
In the healthcare sector, RPM risk may arise when a manufacturer instructs distributors, pharmacies or medical device dealers not to discount below a certain level. It may also occur where a supplier monitors hospital or online prices and pressures dealers to “correct” prices. Bonus systems, supply allocation, campaign support, termination threats or delayed deliveries may become evidence if used to enforce minimum resale prices.
Healthcare companies may have legitimate concerns about product quality, traceability, brand reputation, pharmacovigilance, patient safety and service standards. However, these concerns do not justify fixed or minimum resale prices. Companies should use lawful quality standards rather than price control mechanisms.
7. Exclusive Distribution and Passive Sales
Exclusive distribution is common in pharmaceuticals and medical devices, especially where the supplier needs a distributor to invest in regulatory processes, technical training, hospital relationships, after-sales service or specialized logistics. Exclusive distribution may be lawful if it satisfies the relevant competition law conditions.
However, the active/passive sales distinction is critical. The Vertical Guidelines state that restrictions on passive sales to an exclusive region or customer group exclude the agreement from the block exemption. The Guidelines also explain that internet sales are generally passive sales and that each dealer must, in principle, have the right to make sales over the internet.
In healthcare markets, suppliers should therefore avoid clauses that create absolute territorial protection. A distributor may be restricted from actively targeting another distributor’s exclusive hospital group or region in certain circumstances, but it should not be prohibited from responding to unsolicited customer requests unless a specific exception applies.
8. Market Share Thresholds and Individual Exemption
Vertical agreements may benefit from block exemption if they meet the conditions of the relevant communiqué and do not include prohibited restrictions. The Vertical Guidelines refer to the 30% market share threshold and explain that where the market share is below the threshold, the agreement may benefit from block exemption if it does not include prohibited restrictions; where the threshold is exceeded, Article 5 individual exemption analysis is required.
Article 5 of Law No. 4054 allows exemption where the agreement contributes to economic or technical development, benefits consumers, does not eliminate competition in a significant part of the relevant market and does not restrict competition more than necessary.
This is particularly important for specialty medicines, orphan drugs, medical devices and innovative health technologies. Some restrictions may be defensible if they are necessary for product launch, service quality, patient safety, training or investment recovery. But the restriction must be proportionate. If the same objective can be achieved through less restrictive means, exemption may fail.
9. Abuse of Dominance in Pharmaceutical and Healthcare Markets
Article 6 of Law No. 4054 prohibits the abuse of dominant position in a market for goods or services in Turkey. Dominance itself is not unlawful; abuse is.
Dominance may arise in healthcare markets where a company controls a unique medicine, patented product, essential input, diagnostic technology, medical device, hospital network, health platform, insurance network or healthcare data infrastructure. Market power may also arise from regulatory barriers, reimbursement status, intellectual property rights, physician preference, patient dependency, switching costs or lack of therapeutic substitutes.
Potential abuses may include refusal to supply, discriminatory pricing, excessive pricing in exceptional circumstances, tying, bundling, margin squeeze, predatory pricing, loyalty rebates, exclusive dealing, restricting parallel supply, limiting access to essential technical services or using dominance in one healthcare market to foreclose competitors in another.
For example, a dominant medical device supplier should be cautious when refusing spare parts, maintenance services or consumables to independent service providers. A pharmaceutical company with a strong position in a medicine market should be cautious about supply restrictions that may affect patient access. A private hospital group with regional market power should carefully review exclusive arrangements with insurers or doctors.
10. Intellectual Property, Patents and Competition Law
The pharmaceutical sector depends heavily on patents, regulatory exclusivity, clinical data, trademarks, licensing and R&D investment. Intellectual property rights are lawful and essential for innovation. However, IP rights do not create unlimited freedom from competition law.
Competition issues may arise in patent settlement agreements, licensing restrictions, technology transfer, refusal to license essential technology, product life-cycle management, pay-for-delay type arrangements, excessive exclusivity or practices that delay generic entry without objective justification. Turkish competition law analysis in such cases requires a balance between innovation incentives and market access.
A patent holder may lawfully protect its rights. But if IP rights are used as part of an anti-competitive strategy to exclude competitors beyond the legitimate scope of protection, competition law risk may arise. Companies should therefore review settlement agreements, licensing models and generic entry strategies carefully.
11. Generic Medicines, Biosimilars and Market Entry
Generic and biosimilar competition is essential for reducing healthcare costs and improving access. Competition law concerns may arise where originator companies adopt strategies that delay or block entry without legitimate justification. Such strategies may involve exclusionary agreements, supply restrictions, misleading communications, abusive litigation, bundled rebates or restrictive licensing.
At the same time, originator companies have legitimate rights to protect patents, regulatory exclusivity, product safety and brand reputation. The legal issue is not whether an originator defends its product, but whether the conduct restricts competition beyond what is necessary.
Turkish healthcare regulators continue to issue medicine-related guidance, including on biosimilar medicinal products and licensing matters, which shows that pharmaceutical regulation is an active and developing field. Competition law compliance should therefore be coordinated with regulatory strategy.
12. Labor Market Risks in Pharmaceutical Companies
Competition law applies not only to product markets but also to labor markets. Pharmaceutical and healthcare companies compete for medical representatives, regulatory experts, pharmacists, doctors, nurses, researchers, engineers, sales staff, laboratory professionals and hospital managers.
The Turkish Competition Authority has recently scrutinized labor market arrangements in the pharmaceutical sector. In 2025, the Authority announced the conclusion of an investigation concerning undertakings, most of which operate in the pharmaceutical sector, for alleged violation of Article 4 of Law No. 4054. Reported commentary on the same matter noted that the Board fined a number of pharmaceutical companies in relation to no-poach agreements and wage data exchange.
This area is crucial for healthcare employers. Companies should not agree not to hire each other’s employees, not to compete on wages or to exchange current or future salary information. HR benchmarking must be structured carefully, using aggregated, anonymized and historical data where appropriate. Direct HR conversations between competing employers may create significant Article 4 risk.
13. Private Hospitals, Health Insurance and Network Agreements
Private healthcare institutions often interact with insurance companies, assistance service providers, technical support companies and patient referral systems. These relationships may involve network agreements, service packages, negotiated tariffs, billing rules, pre-authorization systems and claims management.
Competition concerns may arise if insurers coordinate hospital prices, hospitals coordinate their commercial terms toward insurers, or technical support providers facilitate information exchange between competing healthcare institutions. The 2026 investigation announced by the Turkish Competition Authority concerning health insurance, private healthcare institutions and technical or operational support providers demonstrates that these multi-sided healthcare relationships may attract competition scrutiny.
Private hospitals should independently determine their commercial policies. Insurers should avoid arrangements that facilitate coordination among hospitals. Network agreements should be reviewed for exclusivity, discrimination, foreclosure, data exchange and market power issues.
14. Pharmacies and Professional Associations
Pharmacies and professional organizations may also raise competition law issues. Associations may serve legitimate purposes, such as professional standards, public health advocacy and regulatory consultation. However, they should not coordinate prices, fees, commercial terms, supply strategies or market conduct among members.
Law No. 4054 expressly covers decisions and practices of associations of undertakings that restrict competition. Therefore, sectoral bodies, professional associations and chambers should avoid recommended tariffs, collective boycotts, coordinated supply restrictions or sensitive information exchange.
The Turkish Competition Authority has previously investigated matters concerning the Turkish Pharmacists’ Association and related entities, showing that pharmacy-related institutional conduct may fall within competition enforcement.
15. Information Exchange in Healthcare Markets
Information exchange is a major risk in pharmaceutical and healthcare markets. Companies may interact at congresses, industry associations, working groups, public consultations, procurement meetings and scientific events. Not every exchange is unlawful. But exchanging commercially sensitive information between competitors can reduce uncertainty and facilitate coordination.
Sensitive information may include future prices, discounts, rebate strategies, tender participation, customer lists, hospital-level sales, market shares, supply shortages, production volumes, launch dates, reimbursement strategies, salary information and hiring plans.
Market research, sales data and benchmarking may be useful, but they should be aggregated, anonymized, historical and managed by independent third parties where possible. Company-specific current or future data should not be circulated among competitors.
16. Digital Health Platforms and Data-Driven Competition Risks
Digital health platforms, telemedicine services, appointment systems, hospital comparison tools, e-pharmacy-related services, health data analytics, insurance platforms and medical device software can create new competition law questions.
Platform power may arise where doctors, patients, hospitals or insurers depend on a digital intermediary. Data advantages may strengthen market power. Competition concerns may include self-preferencing, discriminatory ranking, exclusive access, tying services, restricting interoperability, use of sensitive business data, algorithmic pricing and platform-facilitated coordination.
Healthcare data is also sensitive from a privacy and regulatory perspective. Compliance with data protection rules does not automatically eliminate competition law risk. A data practice may still raise antitrust concerns if it forecloses rivals, strengthens dominance or limits access to essential digital infrastructure.
17. Merger Control in Pharmaceuticals, Hospitals and Healthtech
Mergers and acquisitions in the pharmaceutical and healthcare sector may require notification to the Turkish Competition Board if they meet applicable legal criteria. Transactions involving pharmaceutical companies, medical device distributors, hospital groups, laboratories, health insurers, digital health platforms, biotech companies and healthtech startups should be screened carefully.
Merger control analysis may focus on product overlaps, pipeline products, geographic overlaps between hospitals, buyer power, public procurement effects, access to distribution channels, innovation, data assets, vertical integration and potential competition.
For example, acquisition of a medical device distributor by a dominant supplier may create foreclosure concerns. A hospital group acquiring regional rivals may affect patient choice and insurer negotiations. A pharmaceutical company acquiring a biotech startup may raise innovation or pipeline concerns.
18. On-Site Inspections and Digital Evidence
The Turkish Competition Authority has broad powers to conduct on-site inspections. Article 15 of Law No. 4054 allows the Board to examine books, documents and other records, request written or oral explanations and inspect undertaking assets.
In pharmaceutical and healthcare investigations, officials may examine emails, messaging applications, tender files, distribution contracts, price lists, hospital negotiations, HR records, salary benchmarking documents, trade association materials, regulatory strategy documents, market access files and digital sales databases.
Companies should have dawn raid protocols. Reception staff, IT teams, legal departments, sales teams, tender teams, HR teams and regulatory affairs departments should know how to respond. Employees must not delete documents, hide devices, provide misleading information or obstruct the inspection.
19. Administrative Fines and Private Damages
Competition law violations may lead to serious administrative fines. Under Law No. 4054, substantive violations of Articles 4, 6 and 7 may result in fines of up to 10% of annual gross revenues, and managers or employees with decisive influence in the infringement may face personal fines of up to 5% of the fine imposed on the undertaking.
Private law consequences are also important. Agreements and association decisions contrary to Article 4 are invalid. Injured parties may claim compensation, and those who restrict competition or abuse dominance are obliged to compensate injured parties.
In healthcare, potential claimants may include hospitals, insurers, pharmacies, patients, distributors, competitors or public institutions. A public hospital may claim loss from bid rigging. A competitor may claim damages from exclusionary conduct. A distributor may challenge unlawful restrictions in a supply agreement.
20. Competition Compliance Program for Healthcare Companies
A healthcare-specific competition compliance program should be practical and risk-based. Generic antitrust policies are not enough for pharmaceutical and healthcare businesses.
The program should include:
Clear rules on competitor contacts at congresses and associations.
Tender compliance procedures for public and private procurement.
Distribution agreement review for RPM, exclusivity and passive sales risks.
Guidance on discount, rebate and bonus systems.
Rules for market access and reimbursement discussions.
HR guidance on no-poach and wage information exchange.
Protocols for clinical, regulatory and commercial information sharing.
Digital health platform data governance.
Merger control screening for acquisitions and joint ventures.
Dawn raid training and document retention rules.
Internal reporting channels and investigation procedures.
Training should be tailored to different teams. Sales teams need RPM and distributor guidance. Tender teams need bid rigging training. Regulatory affairs teams need information exchange awareness. HR teams need labor market antitrust training. Management needs dominance, merger control and dawn raid preparedness.
Conclusion
Turkish Competition Law in the pharmaceutical and healthcare sector is a highly practical and sensitive area. Law No. 4054 applies to medicines, medical devices, hospitals, laboratories, pharmacies, health insurers, digital health platforms and other healthcare undertakings whose conduct affects Turkish markets. The key legal risks include anti-competitive agreements, cartels, bid rigging, resale price maintenance, restrictive distribution, abuse of dominance, labor market collusion, information exchange, merger control violations and private damages exposure.
The sector’s heavy regulation does not remove competition law obligations. On the contrary, regulatory complexity, public procurement, reimbursement pressure, essential products, patient access concerns and information asymmetry make compliance even more important.
Pharmaceutical companies, medical device suppliers, hospitals, insurers, distributors and health technology businesses should review their contracts, pricing practices, tender conduct, HR policies, association participation, digital data use and acquisition strategies from a Turkish competition law perspective. A strong compliance program can reduce investigation risk, protect reputation, prevent administrative fines and support lawful, sustainable growth in Turkey’s healthcare market.
Yanıt yok